# **Background**

Αp	plicant	Inforr	nation

(Carefully read the instructions before completing this form)

	plicant Information					
	Iser Profile information appears below however this					
propos	al will take place (change as necessary). NOTE: You	ur User Profile is always conside	red your c	urrent m	ailing ad	dress.
a.	Applicant Name	Title	C Dr	C Mr	C Ms	C Prof
b.	Institution	Title				
C.	Department					
d.	Address 1					
e.	Address 2					
f.	Address 3					
g.	Address 4					
h.	Country					
i.	City	Province	Postal (	Code		
i.	Phone	Ext	Fax			
k.	e-Mail Address					
I.	Designation					
2 Dr	oject Information					
The titl	e entered when the application was created is indica	ated. Please enter the FULL title	of your res	earch p	roject if it	is not
comple	ete. In addition, ensure the end date of your project is	s updated.				
a.	Project Title					
b.	Is Financial Institution the same as the Research	Institution? (Please select Yes or	No)	Yes	C No	
C.	If No, provide Financial Institution name					
d.	Project Start Date	End Date				
e.	Amount of Funds Requested	Project Co	ost			
f.	Grant category (Please select one from list)					
	Research Grant					
	New Investigator					
	TVCW IIVCStigator					
g.	Type of application. Note: maximum 1 application a	allowed				
	<ul> <li>Initial Application</li> </ul>					
	Re-application					
	Renewal - Indicate previous grant #:					
	granding granding					
h.	The applicants confirm (by choosing "Yes") that as	of June 25, 2016 there is				
	no substantial (more than 50%) overlap with any pe	ending application to any				
	other CCSRI program					
i.	Indicate the number of years of support requested	(up to 4 years)				
				~ V	_	NI-
j.	Is this application being submitted in French? (Note English.) (Please select Yes or No)	e tnat all review panels are condi	ucted in	Yes	С	No

### 3. Participants

Enter the Financial Officer and any Co-Principal investigator, Co-Applicant and Additional Author information applicable to your application. If a participant is an EGrAMS user, use the lookup feature and enter their e-mail address in the field provided as the search criteria. The form will be auto-populated with their contact information as it appears in their user profile. Please attach a curriculum vitae for all participants (excluding the Financial Officer), please use the following format: [lastname\_firstname-CV].

cu	inculum vitae ioi ali particip	dants (excluding the i mancial O	incer), piease use the following format	<u>. [iastriarrie_iiistriarrie-C</u>
a.	Additional Author			
	Name			
	Title			
	Institution			
	Department			
	Address 1			
	Address 2			
	Address 3			
	Address 4			
	Country			
	City		Province	Postal Code
	Telephone		Fax	r ootar oodo
	E-Mail Address		Tux	
h	Co-Applicant			
υ.	Name			
	Title			
	Institution			
	Department			
	Address 1			
	Address 2			
	Address 3			
	Address 4			
	Country		Dravinas	Dootel Code
	City		Province	Postal Code
	Telephone		Fax	
	E-Mail Address			
C.	Co-Principal Investigator			
	Name			
	Title			
	Institution			
	Department			
	Address 1			
	Address 2			
	Address 3			
	Address 4			
	Country			
	City		Province	Postal Code
	Telephone		Fax	
	E-Mail Address			
d.	Financial Officer			
	Name			
	Title			
	Institution			
	Department			
	Address 1			

Address 2 Address 3 Address 4

Country

City Province Postal Code
Telephone Fax

E-Mail Address



# **Applicant info**

### 4. Principal Investigator CV

Attach your abbreviated CV in PDF format. It should include the following information: academic degrees; details of employment since graduation; list of publications during the last 5 working years; and grant support in the past 5 years. Please see the Application Guide for more details. NOTE: For the file name, please use the following format: [lastname\_firstname-CV]. The CCSRI is not a member organization of the Common CV Network, therefore the Common CV should not be used due to Common CV use restrictions.

\_\_\_\_\_

# Certificates

# 8. Certificates required

8.a. B	iohazard/Biosafety			
Indica	te if certificates will be required. Certificates will be requested at the time of funding.			
a.	Does your project require a biohazard certificate? (Please select Yes or No)	C	Yes	C No
C.	Are biohazard certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? (Please select Yes or No)	C	Yes	C No
d.	If yes, give details.			
	List of other institutions			
8.b. A	nimal care			
Indica	te if certificates will be required. Certificates will be requested at the time of funding.			
a.	Does your project require animal care certificates? (Please select Yes or No)	C	Yes	C No
C.	Are animal care certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? (Please select Yes or No)	C	Yes	C No
d.	If yes, give details.			
	Liet of other in other in o			
	List of other institutions			
8.c. E	thics			
Indica	te if certificates will be required. Certificates will be requested at the time of funding.			

· · · · · ·	Certificates for Prevention Research Grants - 2016			3/31	/2016
a.	Does your project require ethics certificates? (Please select Yes or No)	C	Yes	C	No
C.	Are ethics certificates required from other institutions (in case of Co-Principal Investigators and Co-Applicants)? (Please select Yes or No)	C	Yes	C	No
d.	If yes, give details.				
	List of other institutions				
	<b>▲</b>				
•	Numan ambuvania atau aslla invalvament				
9.	Human embryonic stem cells involvement				
	pplicant who proposes the creation or use of human embryonic stem cells, or propos		-		that
would	fall under the federal legislation or the CIHR Guidelines must clearly indicate this fa	ct in	the se	ection	
provid	ed, and must disclose all relevant details in the proposal.				
	Does the proposal involve the use or creation of human embryonic stem cells? (If yes,	C	Yes	C	No
	contact the CCSRI) (Please select Yes or No)				

If yes, is the research reviewed under the auspices of the local ethics review

board? (Do not answer this if the answer above is No)

### **Public summary**

### 10. Public summary - project summary

Provide 2-3 sentences (maximum of 750 characters, including spaces) summarizing the proposal in simple, easy-to-understand, non-technical language, e.g. "Dr X is working to..." or "Dr X will be studying..."

### 11. Public summary - previous research

In 3-5 sentences (maximum of 1000 characters, including spaces), briefly describe in simple, easy-to-understand, non-technical language the current knowledge of this research area, any preliminary work and the context for the proposed study.

### 12. Public summary - project description

In 3-5 sentences (maximum of 1000 characters, including spaces), describe in simple, easy-to-understand, non-technical language the project's rationale, methods and research objectives.

#### 13. Public summary - impact and relevance statement

Detail in 3-5 sentences (maximum of 1000 characters, including spaces) how your studies will contribute to the reduction of cancer incidence rates for Canadians and/or cancer mortality rates for Canadians and/or enhanced quality of life for Canadians living with and beyond cancer.

------ B 7 (00

### **Abstract**

14.	Scie	ntific	abstra	ct
-----	------	--------	--------	----

Provide a detailed summary of your research project (maximum of 4200 characters, including spaces), stating the problem to be investigated, the objectives of the investigation, the methodology to be used, as well as the significance of the research to cancer.

15.	Ke	ywords/	<b>Technical</b>	terms
-----	----	---------	------------------	-------

Provide up to a maximum of ten specific keywords or descriptive technical terms/methodologies that best describe the scientific and technical aspects of your project. NOTE: Enter one keyword or technical term per line.

Keyword/Technical terms	

### 16 Responsiveness statement

Provide a statement (maximum of 1000 characters, including spaces) addressing the appropriateness of the application to this funding opportunity.

### **Proposal**

#### 17. Re-applications and renewal applications

### 17.a. Response to previous critique (re-applications only)

If you are submitting your proposal as a re-application, provide a response (maximum of 2100 characters, including spaces) indicating what improvements have been made as a result of the critiques from the last competition review panel.

#### 17.b. Scientific Officer and reviewer reports (re-applications only)

If you are submitting your proposal as a re-application, attach the scientific officer's report and unabridged reviews from the panel review in PDF format. NOTE: For the file name, please use the following format: [lastname\_firstname-previous\_reviews].

### 17.c. Scientific progress report (renewals only)

Reminder: You are eligible to submit a Renewal application only if you are currently the holder of a fully-funded CCSRI Prevention Research Grant and if the new proposal is a logical continuation of the current fully-funded grant.

Provide a scientific progress summary (maximum of 6300 characters, including spaces) describing the research that has been performed since submission of the last application. The descriptions must be presented in sufficient detail and included enough discussion to permit proper evaluation by scientific experts of the research performed.

### 17.d. Non-Scientific ("Lay") Progress Report (renewals only)

Applicants renewing existing funding must provide a progress report (maximum of 2100 characters, including spaces) covering the previous granting period that is fashioned in easy-to-understand, non-technical terms aimed at a non-scientific audience.

#### 17.e. List of directly supported publications and reprints (renewals only)

Provide a list of publications that were a direct result of the current CCSRI Prevention Research Grant for which you are requesting renewal.

\_\_\_\_

### 18. Table of Contents

OPTIONAL: Include a brief table of contents to help guide the reviewer through the proposal.

#### 19. Proposal

Provide a scientific proposal (maximum of 42,000 characters, including spaces), that includes the following: 1. a scientific outline that clearly states the aims of the project(s) including any previous work done in the area, experiment design, methods and analyses; 2. a description of the expected impact that research results will have on the burden of cancer related to cancer incidence or the advancement of knowledge of how best to reduce the cancer burden; 3. details of the investigator(s) including which member(s) of the research team will be responsible for which aspect of the project and detailed rationale for their inclusion in the project, as well as a description of the research environment where the work will take place; and 4. a description of knowledge translation and exchange strategy and proposed audience(s) as appropriate. NOTE: To insert special characters you must use Alt codes or the special character tool in EGrAMS and not Symbol font.

### 20. Research team contributions

List each research team member (both those named on the grant as a Participant and any others not named), and indicate the % of the project work to be completed by each individual. The total % should add to 100, do not add a % sign in the % of work field.

Participant	Percent of the project work
	•

Page: 10 of 26

Proposal for Prevention Research	Grants - 2016 3/31/2016
	+
	<u> </u>
21. Tables, graphs, charts and associated legends	
	at (maximum of Emarca total) NOTE: For the
OPTIONAL: Attach figures, graphs, charts and legends in PDF form	,
file name, please use the following format: [lastname_firstname-figu	res .
22 List of references	
22. List of references	
The list of references must include the names of all authors, the full	title and the full journal citation.
23. Appendices	
OPTIONAL: Note that all essential information must be included in t	
required to read the material in the appendices. Attachments must be	oe in PDF format only and can not exceed 5ME
per attachment. NOTE: For the file name, please use the following f	ormat: [lastname_firstname-appendix1].
24. Disclosure of commercial interest related to this application	on
If any of the project participants have a financial interest in any com-	mercial venture whose business activities are
related to the subject matter of this grant application, the nature of the	
the nature of the relationship or material interest, the business activi	ties of the company in question, and now
those activities relate, if at all, to the grant application.	
a. All applicants confirm that they have no commercial interest to decl	are (Please select Yes
or No)	The state of the s
b. If no, provide description of commercial Interests	

# Budget

Des	Description 0 1 2 3 Tot							
DIR	DIRECT EXPENSES							
Pro	gram Expenses							
1	Supplies and Expenses							
2	Salaries and Wages							
Tota	al Program Expenses	0.00	0.00	0.00	0.00	0.00		
Equ	ipment							
1	Permanent Equipment							
Tota	al Equipment	0.00	0.00	0.00	0.00	0.00		
тот	TAL DIRECT EXPENSES	0.00	0.00	0.00	0.00	0.00		
тот	TAL EXPENDITURES	0.00	0.00	0.00	0.00	0.00		

Version # Page: 12 of 26

Description	0	1	2	3	Total
Supplies and Expenses	0.00	0.00	0.00	0.00	0.00
Salaries and Wages	0.00	0.00	0.00	0.00	0.00
Permanent Equipment	0.00	0.00	0.00	0.00	0.00
TOTALS	0.00	0.00	0.00	0.00	0.00

### Other funding

### 27. Summary of other funding applied for and received

List all grants currently being applied for, pending, about to be submitted and all grants received, for the entire period covered by this application, for the Principal Investigator and each Co-Principal Investigator. Your documentation should include a list followed by the abstracts for all grants/applications listed and should be submitted in PDF format. Consult the Application Guide for complete instructions, including the correct format. If there are no pending grants to list, indicate by including N/A in the Pending grants section. Applications with missing other funding information or abstracts will be considered incomplete. NOTE: For the file name, please use the following format: [lastname\_firstname-other\_funding]

### 28. Other funding confirmation

The applicants confirm that the attached list contains all required information including \subseteq Yes	□ No
the percentage overlap for each grant and abstracts, as described in the Application	
Guide.	

Page: 14 of 26

### **Review panel**

#### 29. Panel recommendation

All applicants in this competition will be reviewed by the following panel:

- a. Selected Panel
  - PRG Prevention Research Grants Panel

b.

#### 30. Reviewer recommendation

Applicants must suggest the names of at least 3 (5 if submitting application in French) impartial reviewers with the necessary expertise to critically evaluate the application and with whom you do NOT collaborate.

Name	Department	Institution	Phone no.	E-mail address	Areas of expertise

#### 31. Reviewer exclusions

Applicants may suggest individuals they prefer NOT be contacted as potential reviewers (panel members and/or external reviewers). The reason for exclusion (e.g. collaborator, colleague, competitor) should be given. NOTE: any exclusions you list will be viewable to all panel members assigned to review your application.

Name	Reason for exclusion

\_\_\_\_\_

# **Tracking**

### 32. Research tracking information

32.a. Research focus	
Responses are to be limited to the scope of the propo	sed research for the duration of the proposed term. This
information is used solely for statistical/reporting purp	oses and will not be used as part of the scientific review of
the application. Select the research focus of the propo	osal.
I. SECTION I - Research focus (select ONE only)	
Biomedical Research	Clinical Research
Health Services/Systems Research	Social, Cultural, Environmental and Population Health
32.b. Research subject	
Select the research subject(s).	
II. SECTION II - Research subject (select ONE or MOF	RE)

Patients/Study Population	n		
☐ Adult	☐ Pediatric		
Patient Tissue			
□ Adult	☐ Pediatric		
Model System			
Mouse	☐ Drosophila	C. elegans	Zebrafish
	☐ Other		
Cell System			
□hESC	☐ Tumour Initiating Cell	□ Non-embryo-derived	

stem cells (eg. iPS cells)

#### 32.c. Cancer site relevance

Select a maximum of 3 cancer sites where the research will be most relevant. Indicate the degree of relevance (percentage). The total should equal 100%. Only use the Details description field to describe the site if you have selected Other as a site.

Note: Do not enter a % sign with your percentage, only enter the number.

#### III. SECTION III - Cancer site relevance

Cancer site relevance	Percentage	Details

### 32.d. Common Scientific Outline (CSO)

Select a maximum of 3 codes which best describe the research. Full details of the Common Scientific Outline can be found at the International Cancer Research Portfolio website (https://www.icrpartnership.org/CSO.cfm).

IV.	Section	IV - C	Common	Scientific	Outline	(CSO)
						(/

### **Biology**

1.1 - Normal functioning

☐ 1.2 - Cancer initiation: alterations in chromosomes
☐ 1.3 - Cancer initiation: oncogenes and tumour suppressor genes
☐ 1.4 - Cancer progression and metastasis
☐ 1.5 - Resources and infrastructure
Etiology
2.1 - Exogenous factors in the origin and cause of cancer
2.2 - Endogenous factors in the origin and cause of cancer
2.3 - Interactions of genes/genetic polymorphisms with exogenous/endendogenous factors
2.4 - Resources and infrastructure related to etiology
Prevention
☐ 3.1 - Interventions to prevent cancer: personal behaviours that affect cancer risk
3.2 - Nutritional science in cancer prevention
☐ 3.3 - Chemoprevention
☐ 3.4 - Vaccines
3.5 - Complementary and alternative prevention approaches
3.6 - Resources and infrastructure related to prevention
Early Detection, Diagnosis and Prognosis
4.1 - Technology development and/or marker discovery
4.2 - Technology and/or marker evaluation with respect to fundamental parameters of method
4.3 - Technology and/or marker testing in a clinical setting
4.4 - Resources and infrastructure related to detection, diagnosis and prognosis
Treatment
5.1 - Localized therapies – discovery and development
5.2 - Localized therapies – clinical applications
5.3 - Systemic therapies – discovery and development
5.4 - Systemic therapies – clinical applications
5.5 - Complementary and alternative treatment approaches
<ul> <li>□ 5.6 - Complementary and alternative treatment approaches</li> <li>□ 5.7 - Resources and infrastructure related to treatment</li> </ul>
Cancer Control, Survivorship and Outcomes Research
☐ 6.1 - Patient care and survivorship issues
□ 6.2 - Surveillance
□ 6.3 - Behaviour
☐ 6.4 - Cost analyses and healthcare delivery
6.5 - Education and communication
6.6 - End-of-life care
6.7 - Ethics and confidentiality in cancer research
☐ 6.8 - Complementary and alternative approaches for supportive care of patients and survivors
T 6.9 - Resources and infrastructure related to cancer control. survivorship and outcomes research

#### Release form

#### 33. Release form

The CCSRI may be able to secure additional funding from other sources. Applicants are asked to declare their willingness to allow the CCSRI to provide minimal details of their grant to potential donors.

### On condition that:

- the specified information will be shared by CCSRI only with potential donors and for the sole purpose of obtaining additional funding for CCSRI's grant competitions.
- potential donors will be required to declare conflict of interest, and sign a confidentiality agreement before the specified information is released to them by CCSRI.
- it will be held confidential by them and not released to other parties, and will be returned to CCSRI or destroyed
- if the decision is not to fund.
- all information released may be retained by the potential donors if it decides to fund the application, and may be used by the donor in its funding announcements and other communications.

I consent to the sharing of the information specified	described above) with potential donors.	C Yes	C No
(Please select Yes or No)			

### **Head of Department**

### 34. Head of Department/Dean confirmation

This section can only be completed by the Head of the applicant's research department. If the project is to be carried out by the Head of the Department the application must instead be confirmed by the Dean. As the Head of Department/Dean your online acknowledgement indicates that you are aware of the contents of the application being submitted. Answer the question below, then click on Save to complete your confirmation.

I confirm that I am aware of the contents of the application being submitted.	☐ Yes ☐ No
Name of the Head of Department or Dean	
Title	
Research Institution	
Financial Institution	
Date	

### **Executive authority - research host**

### 35. Executive authority of the host research institution

This section can only be completed by an executive authority of the host Institution within which the research will be conducted. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agreement and agree to abide by the terms.		☐ Yes ☐ No
Name of the executive authority - research host		
Title		
Research Institution		
Financial Institution		
Date		

# **Executive authority - financial host**

### 36. Executive authority of the host finance institution

This section can only be completed by an executive authority of the Institution within which the funds will be administered. As the Executive Authority your online acknowledgement indicates that you have read and understood the Terms of the Host Institution/CCS Agreement. Answer the question below, then click on Save to complete your confirmation.

I confirm that I have read and understood the Host Institution / CCS Agree agree to abide by the terms.	ement, and Yes No
Name of the executive authority - financial host	
Title	
Research Institution	
Financial Institution	
Date	

### Post submission publications

### 37. Post submission publications

Publication lists included in this section prior to submission will be removed. This section should only be used after you have submitted your application. Attach a PDF document of your acceptance e-mail/letter for newly accepted publications. You may update this attachment at any time after you've submitted your application, up until the panel meeting. NOTE: For the file name, use the following format [lastname\_firstname\_publications\_yyyymmdd], where yyyymmdd is the current date.

\_\_\_\_\_

# **CCSRI**

# 38. CCSRI revised lay summary

This section of the application is for internal CCSRI use only.